Next Article in Journal
Borylated Five-Membered Ring Iminosugars: Synthesis, Spectroscopic Analysis, and Biological Evaluation for Glycosidase Inhibition and Anticancer Properties for Application in Boron Neutron Capture Therapy (BNCT)—Part 1
Previous Article in Journal
Synthesis and Structure-Affinity Relationships of Receptor Ligands with 1,3-Dioxane Structure
Previous Article in Special Issue
Real-World Safety of Vedolizumab in Inflammatory Bowel Disease: A Retrospective Cohort Study Supported by FAERS Signal Analysis
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
This is an early access version, the complete PDF, HTML, and XML versions will be available soon.
Article

Pharmacovigilance Insights into Ibuprofen’s Neuropsychiatric Safety: A Retrospective Analysis of EudraVigilance Reports

by
Cristina Anamaria Buciuman
1,
Carmen Maximiliana Dobrea
2,
Anca Butuca
2,
Adina Frum
2,
Felicia Gabriela Gligor
2,
Mihai O. Botea
3,
Laura Grațiela Vicaș
1,3,
Mariana Eugenia Mureșan
3,
Octavia Gligor
3,*,
Florin Maghiar
3,
Alexia Manole
3 and
Claudiu Morgovan
2
1
Faculty of Pharmacy, Carol Davila University of Medicine and Pharmacy, 6 Traian Vuia Str., 020956 Bucharest, Romania
2
Preclinical Department, Faculty of Medicine, “Lucian Blaga” University of Sibiu, 550169 Sibiu, Romania
3
Faculty of Medicine and Pharmacy, University of Oradea, 10, 1 December Square, 410073 Oradea, Romania
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2025, 18(9), 1301; https://doi.org/10.3390/ph18091301
Submission received: 22 June 2025 / Revised: 22 August 2025 / Accepted: 28 August 2025 / Published: 29 August 2025
(This article belongs to the Special Issue Therapeutic Drug Monitoring and Adverse Drug Reactions: 2nd Edition)

Abstract

Background/Objectives: Mental health awareness is rising; thus, neurological and psychiatric side effects also benefit from increased attention from the medical and scientific community. Ibuprofen is a well-known non-steroidal anti-inflammatory drug (NSAID) that is often available over-the counter (OTC) for both adults and children, expressing good efficacy in reducing pain and fever through non-selective cyclooxygenase inhibition. As ibuprofen has already been associated with different neuropsychiatric disorders, the aim of this study was to perform an up-to-date analysis of such signals detected in the cases reported in EudraVigilance (EV). Methods: The disproportionality analysis offered a contextual insight into the real-world situation depicted in the analyzed database. Results: From the total cases reported for ibuprofen (n = 58,911), 13.9% contained nervous system disorders (n = 8214) and 10.7% entailed psychiatric disorders (n = 6295). The cases were distributed between all age groups, with a sensible higher incidence in teenagers and in women in general. Severe cases, including deaths, have been reported. By comparison with ketoprofen, acetylsalicylic acid, and diclofenac, ibuprofen presented a higher probability of reporting psychiatric and behavioral symptoms. Regarding cognitive and attention disorders and disturbances, no disproportionate signal was observed between ibuprofen and all other NSAIDs. Sleep disturbances (hypersomnia, narcolepsy and sleep paralysis) are reported as more probable for ibuprofen than for acetylsalicylic acid, naproxen, and diclofenac. A higher risk of reporting suicidal and self-injurious behaviors was noted for ibuprofen versus all other selected NSAIDs. A limitation of the study can be noted as due to suspected causality, not an established one, and EV reports cannot accurately determine adverse drug reaction frequencies. Conclusions: Considering that ibuprofen is easily accessible as an OTC drug and the higher probability of reporting several neuropsychiatric adverse effects as shown by this study, patient counseling, when possible, and general education for the public are valuable tools in managing these adverse reactions.
Keywords: pharmacovigilance; neuropsychiatric safety; ibuprofen; neuropsychiatric disorders; NSAIDs pharmacovigilance; neuropsychiatric safety; ibuprofen; neuropsychiatric disorders; NSAIDs

Share and Cite

MDPI and ACS Style

Buciuman, C.A.; Dobrea, C.M.; Butuca, A.; Frum, A.; Gligor, F.G.; Botea, M.O.; Vicaș, L.G.; Mureșan, M.E.; Gligor, O.; Maghiar, F.; et al. Pharmacovigilance Insights into Ibuprofen’s Neuropsychiatric Safety: A Retrospective Analysis of EudraVigilance Reports. Pharmaceuticals 2025, 18, 1301. https://doi.org/10.3390/ph18091301

AMA Style

Buciuman CA, Dobrea CM, Butuca A, Frum A, Gligor FG, Botea MO, Vicaș LG, Mureșan ME, Gligor O, Maghiar F, et al. Pharmacovigilance Insights into Ibuprofen’s Neuropsychiatric Safety: A Retrospective Analysis of EudraVigilance Reports. Pharmaceuticals. 2025; 18(9):1301. https://doi.org/10.3390/ph18091301

Chicago/Turabian Style

Buciuman, Cristina Anamaria, Carmen Maximiliana Dobrea, Anca Butuca, Adina Frum, Felicia Gabriela Gligor, Mihai O. Botea, Laura Grațiela Vicaș, Mariana Eugenia Mureșan, Octavia Gligor, Florin Maghiar, and et al. 2025. "Pharmacovigilance Insights into Ibuprofen’s Neuropsychiatric Safety: A Retrospective Analysis of EudraVigilance Reports" Pharmaceuticals 18, no. 9: 1301. https://doi.org/10.3390/ph18091301

APA Style

Buciuman, C. A., Dobrea, C. M., Butuca, A., Frum, A., Gligor, F. G., Botea, M. O., Vicaș, L. G., Mureșan, M. E., Gligor, O., Maghiar, F., Manole, A., & Morgovan, C. (2025). Pharmacovigilance Insights into Ibuprofen’s Neuropsychiatric Safety: A Retrospective Analysis of EudraVigilance Reports. Pharmaceuticals, 18(9), 1301. https://doi.org/10.3390/ph18091301

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop